Clinical trial
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00182689 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00182689 |
|---|---|
| Title | Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer |
| Official title | A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 89 |
| Start date | Jul 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: